REVA Medical, Inc. Contracts & Agreements
61 Contracts & Agreements
- Business Finance (1 contract)
- Business Operations (1)
- Human Resources (10)
- Intellectual Property (4)
- Real Estate (2)
- Uncategorized (43)
- Order of the Bankruptcy Court, dated February 19, 2020, confirming the Prepackaged Chapter 11 Plan of REVA Medical, Inc (Filed With SEC on March 5, 2020)
- Restructuring Support Agreement, dated December 23, 2019 by and between the debtors and the Supporting Lenders (Filed With SEC on January 15, 2020)
- Amendment #5 dated April 2, 2019 to the Exclusive License Agreement Number 2, by and between Rutgers, The State University of New Jersey and the Company, dated July 30, 2018 (Filed With SEC on April 8, 2019)
- Executive Employment Agreement, effective as of January 4, 2019, by and between the Company and Leigh Elkolli (Filed With SEC on January 17, 2019)
- Amendment #4 to Exclusive License Agreement Number 2, by and between Rutgers, The State University of New Jersey and the Company, dated July 30, 2018 (Filed With SEC on August 3, 2018)
- Form of Restricted Stock Unit Agreement (2010 Equity Incentive Plan) (Filed With SEC on March 7, 2018)
- Form of Restricted Stock Agreement (2010 Equity Incentive Plan) (Filed With SEC on March 7, 2018)
- Consulting Agreement, dated July 5, 2017, by and between REVA Medical, Inc. and Brandi L. Roberts (Filed With SEC on March 7, 2018)
- Consulting Agreement, dated July 13, 2017, by and between REVA Medical, Inc. and Robert K. Schultz (Filed With SEC on March 7, 2018)
- Consulting Agreement, dated September 11, 2017, by and between REVA Medical, Inc. and Katrina L. Thompson (Filed With SEC on March 7, 2018)
- Executive Employment Agreement, dated August 28, 2017 by and between REVA Medical, Inc. and Brandi L. Roberts (Filed With SEC on November 7, 2017)
- Sixth Amendment to Telecom Business Center NNN Lease between Gildred Building Company and REVA Medical, Inc (Filed With SEC on November 7, 2017)
- CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISKS [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION... (Filed With SEC on November 9, 2016)
- FIRST AMENDMENT TO CONVERTIBLE NOTE DEED (Filed With SEC on February 17, 2016)
- EXCLUSIVE LICENSE AGREEMENT NUMBER Between REVA Medical, Inc. and RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (Filed With SEC on November 9, 2015)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 21, 2015)
- AMENDMENT #2 to Exclusive License Agreement Number 2 (Filed With SEC on November 6, 2014)
- First Amendment to Distribution Option Agreement (Filed With SEC on March 17, 2014)
- REVA MEDICAL, INC. Independent Director Compensation Policy (Filed With SEC on March 17, 2014)
- 5751 Copley Drive, Suite B, San Diego, CA 92111 ###-###-#### ###-###-#### (FAX) www.teamreva.com (Filed With SEC on March 17, 2014)
- REVA MEDICAL, INC. Independent Director Compensation Policy (Filed With SEC on February 27, 2013)
- FIFTH AMENDMENT TO TELECOM BUSINESS CENTER NNN LEASE (Filed With SEC on November 23, 2011)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on November 12, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on November 12, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on November 12, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on November 12, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on November 12, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on November 12, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on November 12, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on November 12, 2010)
- Broker Code Adviser Code (Filed With SEC on November 12, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on October 22, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on October 22, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on October 22, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on October 22, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on October 22, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on October 22, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on October 22, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on October 22, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on October 22, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on September 21, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on September 21, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
- Adverse long-term reactions, including the potential for restenosis (Filed With SEC on August 13, 2010)
